Encenicline
As of the edition of 20 October 2026, Encenicline is a small molecule: stopped in 2017; acts on CHRNA7.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Small molecule
- Registered trials
- 14, 6 stopped early
- Disease areas
- Mental health; Nervous system; Chemically induced; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Encenicline.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA7 | Neuronal acetylcholine receptor subunit alpha-7 | P36544 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| Phase 3 | 7 | 3 | 0 | 4 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| FORUM Pharmaceuticals | Lead sponsor of trials | 2008 to now |
| Tanabe Pharma | Lead sponsor of trials | 2012 to now |